Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals with High-Risk of Lung Cancer Undergoing LDCT Screening.

NARecruitingINTERVENTIONAL
Enrollment

3,200

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
Lung Cancer
Interventions
DIAGNOSTIC_TEST

Exhaled breath condensate sampling

Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed.

DIAGNOSTIC_TEST

Blood sampling

A venous blood sample will be taken for further biomarker analysis.

PROCEDURE

LDCT

LDCT scan will be performed.

DIAGNOSTIC_TEST

Vital signs

Blood pressure, weight, height, pulse, oxygen saturation will be measured.

DIAGNOSTIC_TEST

Spirometry

Spirometry will be performed.

Trial Locations (3)

12808

NOT_YET_RECRUITING

General University Hospital in Prague, Prague

65653

RECRUITING

Masaryk Memorial Cancer Institute, Brno

77900

NOT_YET_RECRUITING

University Hospital, Olomouc

Sponsors
All Listed Sponsors
collaborator

Cancer Research Foundation CR

UNKNOWN

lead

The Institute of Molecular and Translational Medicine, Czech Republic

OTHER